Mechanistic Study of Inspiratory Training in Childhood Asthma (MICA)

Obesity Clinical Trial

— MICA  

Official title:

Mechanistic Study of Inspiratory Training in Childhood Asthma (MICA)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05945355
• Other study ID #: Pro00112858
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 1, 2024
• Est. completion date: October 30, 2027

Study information

• Verified date: July 2023
• Source: Duke University
• Contact: Jason Lang, MD
• Phone: 9196843364
• Email: jason.lang[@]duke.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is single-center cross-sectional mechanistic study in lean and obese children with moderate-severe asthma, followed by a randomized, SHAM-controlled trial of Inspiratory Training (IT). The primary outcome is to describe the contributions of inspiratory muscle dysfunction (IMD) and Small Airway Dysfunction (SAD) to obesity-related versus non-obesity-related asthma. The study will involve training (IT) for 8 weeks at three intensity levels (SHAM, low and high). Target dose: 150 inspirations three times weekly. The population includes 6 to 17-year-old children with moderate to severe asthma and with a body mass index qualifying as normal habitus (BMI 5th to 84th CDC percentile) or obese habitus (≥95th percentile BMI and less than 170% of the 95th CDC percentile). Participants will be involved for 10 weeks. The investigators will use analysis of covariance (ANCOVA) to estimate and test the difference in mean values of baseline measures between obese and non-obese cohorts. Covariates will include age, sex (male/female), race/ethnicity, baseline asthma severity (NAEPP step 2 vs ≥3), and atopy status

Description:

Cross-sectional analytic study of pulmonary mechanics comparing lean and obese children with asthma followed by a randomized, SHAM-controlled 3-arm intervention trial of inspiratory training on small airway dysfunction and inspiratory muscle function. The central objective of the MICA (Mechanistic Study of Inspiratory Training in Childhood Asthma) study is to assess key respiratory mechanisms in 6-17 year olds with symptomatic asthma (with and without obesity) in response to IT. Our central hypothesis is that obesity promotes dyspnea and worse asthma control via inspiratory muscle fatigue/dysfunction (IMD) and small airway dysfunction (SAD), and that IT will improve inspiratory muscle function and small airway measures. The sample size calculations and main analyses for the IT trial are designed as a traditional parallel arm intervention trial (any dose IT vs. SHAM control) with visits 1-2 serving as the baseline evaluation and the main IT endpoints being collected at the 8-week visit. In depth phenotyping involving measures of respiratory mechanics and muscle functioning and a RCT involving inspiratory training will address these objectives.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 76
• Est. completion date: October 30, 2027
• Est. primary completion date: October 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

• 6-17 years of age
• Documented clinician-diagnosed asthma
• Currently requiring 2 or more controller prescriptions to treat disease (i.e. moderate to severe persistent disease)
• Either obese (=95th percentile BMI and less than 170% of the 95th CDC percentile) or have a normal BMI (BMI 5th to 84th CDC percentile)

Exclusion Criteria:

• ACT (asthma control test) score <17
• Ever intubated for asthma
• FEV1 < 50% of predicted at enrollment
• Currently pregnant
• Legal guardian unable to consent in English or Spanish
• Any major chronic illness that, in the opinion of the PI, would interfere with participation
• Younger than 6 years of age

Related Conditions & MeSH terms

• Asthma
• Asthma in Children
• Obesity
• Pediatric Asthma
• Pediatric Obesity

Intervention

Device:
• Pro2 - Low Dose - 40% of participant's MIP
Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).
• Pro2 - High Dose - 75% of participant's MIP
Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).
• Pro2 - SHAM - 15% of participant's MIP
Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that participants achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).

Locations

Country	Name	City	State
United States	Duke Health Center Creekstone	Durham	North Carolina
United States	Duke Healthy Lifestyles Clinic	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Small airway dysfunction as measured by impulse oscillometry		10 weeks
Other	Small airway dysfunction as measured by residual volume		10 weeks
Primary	Number of participants with inspiratory muscle dysfunction in obesity-related versus non-obesity-related asthma		10 weeks
Primary	Number of participants with small airway dysfunction in obesity-related versus non-obesity-related asthma		10 weeks
Secondary	Inspiratory muscle endurance (sustained maximal inspiratory pressure)		10 weeks